FDA pain market moves 'creating huge opportunities'

23rd December 2013

The US opioid market is dominated by non tamper-resistant formulations, but the Food and Drug Administration’s promotion of TRF therapies could well result in the departure of non-TRF treatments from the market, say new forecasts.

Purdue Pharma’s Oxycontin is the only opioid pain treatment among the 50 top-selling pharmaceuticals in the USA, and unless the FDA mandates TRF therapies, further genericisation and lack of novel mechanism of actions (MOAs) will ensure opioids are absent from the top 50 by 2018, warns the study, from Frost & Sullivan.

Read article at source pharmatimes.com

Leave a Reply

Your email address will not be published.

12 − 10 =

« back to posts